I do not think this goes above 20 on Monday but should get there in the near term though. The company is still undervalued and most of the price targets are well above the current PPS. The affect on inspection on the products in question will have at the max 8% impact on revenues. That too is the worst case. It could be much lesser.
The EPS for the next quarter will be reduced accordingly by analysts and if the impact is not worse, as thought by most, this will bounce right back. Also, in terms of chart, it bounced nicely off the 52 week low and with a good volume. So this has a potential to form a double bottom. The only factor is how much the cost will increase on the manufacturing changes that they will be doing based on FDA feedback. I think this is short term panic selling as we saw at the open on Friday and the bounce back and hold of the 19 line through the end of the day when the markets were falling. This will go back to 22 in the near term when people realize that the impact is not as bad as though and the FY12 EPS is still intact.